PIPERACILLIN AND TAZOBACTAM FOR INJECTION POWDER FOR SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

PIPERACILLIN (PIPERACILLIN SODIUM); TAZOBACTAM (TAZOBACTAM SODIUM)

から入手可能:

FRESENIUS KABI CANADA LTD

ATCコード:

J01CR05

INN（国際名）:

PIPERACILLIN AND BETA-LACTAMASE INHIBITOR

投薬量:

36G; 4.5G

医薬品形態:

POWDER FOR SOLUTION

構図:

PIPERACILLIN (PIPERACILLIN SODIUM) 36G; TAZOBACTAM (TAZOBACTAM SODIUM) 4.5G

投与経路:

INTRAVENOUS

パッケージ内のユニット:

15G/50G

処方タイプ:

Prescription

治療領域:

EXTENDED-SPECTRUM PENICILLINS

製品概要:

Active ingredient group (AIG) number: 0225919008; AHFS:

認証ステータス:

APPROVED

承認日:

2017-07-07

製品の特徴

_ _
_Piperacillin and Tazobactam for Injection _
_Page 1 of 43_
PRODUCT MONOGRAPH
INCUDING PATIENT MEDICATION INFORMATION
PR
PIPERACILLIN AND TAZOBACTAM FOR INJECTION
Piperacillin Sodium/Tazobactam Sodium
Lyophilized Powder for Injection
For Intravenous Use Only
MANUFACTURER’S STANDARD
PIPERACILLIN 12 G (AS PIPERACILLIN SODIUM) AND TAZOBACTAM 1.5 G (AS
TAZOBACTAM SODIUM) PER VIAL
PIPERACILLIN 36 G (AS PIPERACILLIN SODIUM) AND TAZOBACTAM 4.5 G (AS
TAZOBACTAM SODIUM) PER VIAL
Antibiotic/β-lactamase Inhibitor
FRESENIUS KABI CANADA LTD.
165 Galaxy Blvd, Suite 100
Toronto, Ontario
M9W 0C8
Date of Revision:
November 18, 2020
Submission Control No.: 246054
_ _
_Piperacillin and Tazobactam for Injection _
_Page 2 of 43_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................5
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
....................................................................................................8
DRUG INTERACTIONS
..................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................14
OVERDOSAGE
................................................................................................................18
ACTION AND CLINICAL PHARMACOLOGY
............................................................19
STORAGE AND STABILITY
..........................................................................................21
SPECIAL HANDLING INSTRUCTIONS
......................................................